Similar Risk of Death Between Patients With HFimpEF, LVEF Above 40% in DELIVER Trial
January 24th 2024An analysis of the DELIVER trial also revealed an association between dapagliflozin treatment and reduced risk of cardiovascular death among individuals with heart failure with improved ejection fraction (HFimpEF).
Read More
Sarepta Therapeutics has started screening participants for a Phase 3 clinical trial to test its gene therapy candidate SRP-9003 in children with limb-girdle muscular dystrophy type 2E; wastewater testing points to a new COVID-19 infection wave fueled by the JN.1 variant; most patients on anti-obesity medications kept at least some weight off up to a year after they stopped taking them.
Read More
Sacituzumab Govitecan Monotherapy for NSCLC Disappoints in EVOKE-01 Trial Update
January 23rd 2024The TROP-2–directed antibody drug conjugate is currently being investigated as a monotherapy and a combination therapy for non–small cell lung cancer (NSCLC) in 3 trials: phase 3 EVOKE-01, phase 2 EVOKE-02, and phase 3 EVOKE-03.
Read More
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
January 23rd 2024Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
Study Highlights Need for Additional Caregiver Support in Higher-Risk MDS
January 23rd 2024The study, which pulled self-reported data from online bulletin boards across the US, Canada, and the United Kingdom in 2020, found that the degree of burden varied based on patient disease stage, among other factors.
Read More
What We’re Reading: CAR T Therapy Warning; Child Flu Cases; Alzheimer Blood Test
January 23rd 2024Pharmaceutical companies required to update prescribing information for chimeric antigen receptor (CAR) T-cell therapies; Texas dashboard reports a 40% increase in pediatric flu cases; a blood test shows high accuracy for Alzheimer disease biomarkers.
Read More
Analysis Explores Gene Therapy’s Potential to Be Cost-Effective in SCD
January 22nd 2024This new economic valuation of the societal and health care benefits of gene therapy to treat sickle cell disease (SCD) concludes the highly personalized treatment has potential to be cost effective if priced below $2 million.
Read More
What We’re Reading: Global Pandemic Accord; New Abortion Initiatives; Cervical Cancer Increasing
January 22nd 2024Meeting the 2024 deadline for an international agreement on pandemic response may not happen; the Biden administration announces measures to counter restrictive state laws on abortion; cervical cancer incidence declines as more women receive the human papillomavirus vaccine.
Read More
Bolus Insulin Injection Frequency, Smart Pen Engagement Linked With Glycemic Control in T1D
January 22nd 2024A real-world study conducted across 9 European countries found that bolus injection frequency and engagement with a smart pen to administer insulin were associated with improved glycemic control among young adult patients with type 1 diabetes (T1D).
Read More
VR-Based Pulmonary Rehabilitation More Effective in Patients With COPD, Study Says
January 21st 2024Virtual reality (VR) combined with pulmonary rehabilitation was more effective than pulmonary rehabilitation alone in improving the pulmonary function, exercise capacity, and mental health of patients with chronic obstructive pulmonary disease (COPD).
Read More
Topical Corticosteroids: The Preferred First-Line Treatment for Pediatric Alopecia Areata
January 20th 2024A survey of pediatric dermatologists revealed that topical corticosteroids are the most common first-line treatment for children with alopecia areata, regardless of age or hair loss severity.
Read More